Tianlong Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Tianlong Wang has a total of 335 co-authors. Here are the top co-authors by number of shared publications:
Wei Xiao
Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China
24 shared publicationsLong Fan
16 shared publicationsYang Liu
Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China
14 shared publicationsHuiqun Fu
Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China
12 shared publicationsShuyi Yang
Department of Anesthesiology, Xuanwu Hospital Capital Medical University, National Clinical Research Center for Geriatric, Beijing, People’s Republic of China
10 shared publicationsGuang Feng
Department of Anesthesiology, Xuanwu Hospital, Capital Medical University, Beijing, China
9 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
Cerebral infarction and cerebrovascular stenosis: potential risk factors for intraoperative hypothermia in elderly patients undergoing video-assisted thoracic surgery
Intraoperative hypothermia increases the risk of various perioperative complications and delays postoperative recovery. Elderly patients exhibit impaired thermoregulatory capacity, yet the risk factors for hypothermia during video-assisted thoracic surgery still remain unclear. A retrospective analysis was conducted on patients aged ≥ 65 years who underwent video-assisted thoracic surgery at Xuanwu Hospital, Capital Medical University, from January 1, 2024, to October 1, 2025. Data on patient characteristics, preoperative and postoperative assessments, and intraoperative parameters were extracted from electronic record system and anesthesia records. A total of 401 patients were included, with an overall incidence of intraoperative hypothermia of 60.8%. Multivariate analysis identified cerebral infarction history (OR = 3.054, 95% CI 1.434–6.504, P = 0.004) and moderate to severe cerebrovascular stenosis (OR = 4.701, 95% CI 1.746–12.657, P = 0.002) as independent risk factors. Preoperative arrhythmia (OR = 2.653, 95% CI 1.501–4.691, P < 0.001) was associated with an increased risk of inadvertent hypothermia. Higher body mass index (BMI) was identified as a protective factor against hypothermia (OR = 0.928, 95% CI 0.872–0.988, P = 0.02). Intraoperative hypothermia leads to an increased incidence of postoperative pulmonary complications ( P < 0.001). The mean hospital stay was longer in the hypothermia group compared to the none-hypothermia group (9 vs. 8 days, P = 0.011). The findings indicate that preoperative cerebral infarction, moderate to severe cerebrovascular stenosis and arrhythmia may increase the risk of intraoperative hypothermia. For such high risk patients, targeted enhanced warming measures should be prioritized to reduce the incidence of this complication.
- 8 October 2026
- Published by Springer Nature in Journal of Cardiothoracic Surgery
Open AccessCerebral infarction and cerebrovascular stenosis: potential risk factors for intraoperative hypothermia in elderly patients undergoing video-assisted thoracic surgery
Intraoperative hypothermia increases the risk of various perioperative complications and delays postoperative recovery. Elderly patients exhibit impaired thermoregulatory capacity, yet the risk factors for hypothermia during video-assisted thoracic surgery still remain unclear. A retrospective analysis was conducted on patients aged ≥ 65 years who underwent video-assisted thoracic surgery at Xuanwu Hospital, Capital Medical University, from January 1, 2024, to October 1, 2025. Data on patient characteristics, preoperative and postoperative assessments, and intraoperative parameters were extracted from electronic record system and anesthesia records. A total of 401 patients were included, with an overall incidence of intraoperative hypothermia of 60.8%. Multivariate analysis identified cerebral infarction history (OR = 3.054, 95% CI 1.434–6.504, P = 0.004) and moderate to severe cerebrovascular stenosis (OR = 4.701, 95% CI 1.746–12.657, P = 0.002) as independent risk factors. Preoperative arrhythmia (OR = 2.653, 95% CI 1.501–4.691, P < 0.001) was associated with an increased risk of inadvertent hypothermia. Higher body mass index (BMI) was identified as a protective factor against hypothermia (OR = 0.928, 95% CI 0.872–0.988, P = 0.02). Intraoperative hypothermia leads to an increased incidence of postoperative pulmonary complications ( P < 0.001). The mean hospital stay was longer in the hypothermia group compared to the none-hypothermia group (9 vs. 8 days, P = 0.011). The findings indicate that preoperative cerebral infarction, moderate to severe cerebrovascular stenosis and arrhythmia may increase the risk of intraoperative hypothermia. For such high risk patients, targeted enhanced warming measures should be prioritized to reduce the incidence of this complication.
- Open Access
Efficacy of high-flow nasal cannula versus conventional face mask oxygen therapy on ipsilateral cerebral haemodynamics during the immediate post-extubation phase following carotid endarterectomy: protocol for a randomised controlled trial
Introduction: Cerebral hyperperfusion syndrome (CHS) is a severe complication following carotid endarterectomy (CEA). During emergence from general anaesthesia, residual anaesthetics induce mild respiratory depression and carbon dioxide accumulation, exacerbating hyperperfusion risks via hypercapnia-induced cerebral vasodilation. High-flow nasal cannula (HFNC) effectively reduces excessively elevated pressure of arterial carbon dioxide via multiple mechanisms including anatomical dead space washout. This trial aims to evaluate the effects of HFNC versus conventional mask oxygen therapy on ipsilateral cerebral haemodynamics during the immediate post-extubation phase in patients undergoing CEA. Methods and analysis: This single-centre, randomised controlled trial will allocate 66 adult patients scheduled for elective CEA in a 1:1 ratio to receive either HFNC or a conventional oxygen mask for 10 min immediately following tracheal extubation. The primary outcome is the ipsilateral relative middle cerebral artery blood flow velocity (rMCAv) at 10 minutes post-extubation. Secondary outcomes encompass continuous high-frequency trajectories of ipsilateral rMCAv and invasive arterial blood pressure, their haemodynamic variability (coefficient of variation) and hyperperfusion burden (area under the curve), absolute changes in arterial blood gases (ABG) and clinical outcomes evaluated up to hospital discharge (including abnormal ipsilateral cerebral hyperperfusion, postoperative headache, CHS, incidence of postoperative acute ischaemic stroke or transient ischaemic attack and length of stay). Longitudinal high-frequency data will be analysed using linear mixed-effects models while pre-intervention and post-intervention ABG variations will be evaluated via analysis of covariance. Ethics and dissemination: The protocol (V.2.0, 30 June 2025) complies with the Declaration of Helsinki and was approved by the Institutional Review Board of Xuanwu Hospital, Capital Medical University (LYS[2025]-NO.147-002). Written informed consent will be obtained from all participants prior to inclusion. Results will be submitted for publication in peer-reviewed journals. Trial registration number: ChiCTR2500105199.
Open AccessEfficacy of high-flow nasal cannula versus conventional face mask oxygen therapy on ipsilateral cerebral haemodynamics during the immediate post-extubation phase following carotid endarterectomy: protocol for a randomised controlled trial
Introduction: Cerebral hyperperfusion syndrome (CHS) is a severe complication following carotid endarterectomy (CEA). During emergence from general anaesthesia, residual anaesthetics induce mild respiratory depression and carbon dioxide accumulation, exacerbating hyperperfusion risks via hypercapnia-induced cerebral vasodilation. High-flow nasal cannula (HFNC) effectively reduces excessively elevated pressure of arterial carbon dioxide via multiple mechanisms including anatomical dead space washout. This trial aims to evaluate the effects of HFNC versus conventional mask oxygen therapy on ipsilateral cerebral haemodynamics during the immediate post-extubation phase in patients undergoing CEA. Methods and analysis: This single-centre, randomised controlled trial will allocate 66 adult patients scheduled for elective CEA in a 1:1 ratio to receive either HFNC or a conventional oxygen mask for 10 min immediately following tracheal extubation. The primary outcome is the ipsilateral relative middle cerebral artery blood flow velocity (rMCAv) at 10 minutes post-extubation. Secondary outcomes encompass continuous high-frequency trajectories of ipsilateral rMCAv and invasive arterial blood pressure, their haemodynamic variability (coefficient of variation) and hyperperfusion burden (area under the curve), absolute changes in arterial blood gases (ABG) and clinical outcomes evaluated up to hospital discharge (including abnormal ipsilateral cerebral hyperperfusion, postoperative headache, CHS, incidence of postoperative acute ischaemic stroke or transient ischaemic attack and length of stay). Longitudinal high-frequency data will be analysed using linear mixed-effects models while pre-intervention and post-intervention ABG variations will be evaluated via analysis of covariance. Ethics and dissemination: The protocol (V.2.0, 30 June 2025) complies with the Declaration of Helsinki and was approved by the Institutional Review Board of Xuanwu Hospital, Capital Medical University (LYS[2025]-NO.147-002). Written informed consent will be obtained from all participants prior to inclusion. Results will be submitted for publication in peer-reviewed journals. Trial registration number: ChiCTR2500105199.
- Open Access
- 10 June 2026
- Published by Springer Nature in BMC Anesthesiology
Effects of remote ischemic preconditioning on postoperative gastrointestinal function in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled trial
Postoperative gastrointestinal function is one of the important factors influencing the prognosis of off-pump coronary artery bypass grafting (OPCAB) patients. Remote ischemic preconditioning (RIPC) is a noninvasive intervention that may offer multiorgan protection. This study aimed to evaluate the impact of preoperative RIPC on postoperative gastrointestinal function and clinical outcomes in OPCAB patients. This prospective, assessor- and statistician-blinded, sham-controlled, randomized clinical trial included 106 patients scheduled to undergo elective OPCAB. They were randomly assigned to the RIPC (n = 53) or sham-RIPC (n = 53) group. The RIPC group received bilateral upper limb ischemia/reperfusion cycles (200 mmHg, 5-min ischemia/5-min reperfusion, repeated for 5 cycles) twice daily for 3 consecutive preoperative days. The primary outcome was the incidence of postoperative gastrointestinal intolerance (POGI), defined as an I-FEED score of 3-5 within 7 days postoperatively. The secondary outcomes included markers of intestinal injury (intestinal fatty acid-binding protein (I-FABP)), systemic inflammation (interleukin-6 (IL-6), C-reactive protein (CRP)), and S-100 protein beta subunit (S-100β). The exploratory outcomes comprised gut microbiota analysis and other clinical parameters. The incidence of POGI was lower in the RIPC than in the sham-RIPC group (35.4% vs. 56.5%, P = 0.040). The postoperative serum levels of I-FABP, IL-6, CRP, and S-100β were also lower in the RIPC group. Moreover, the relative abundance of Gemella and Dorea decreased in the RIPC group postoperatively. Notably, the abundance of Gemella showed a positive correlation with the postoperative levels of I-FABP and IL-6, whereas that of Dorea exhibited a positive correlation with the postoperative I-FABP levels. The preoperative application of RIPC was associated with a lower risk of POGI, with no observed safety concerns. This effect of RIPC may be related to attenuated intestinal mucosal injury, reduced systemic inflammation, and potential modulation of the gut microbiota. This study was registered on May 30, 2024 (ChiCTR2400085044).
- 10 June 2026
- Published by Springer Nature in BMC Anesthesiology
Open AccessEffects of remote ischemic preconditioning on postoperative gastrointestinal function in patients undergoing off-pump coronary artery bypass grafting: a randomized controlled trial
Postoperative gastrointestinal function is one of the important factors influencing the prognosis of off-pump coronary artery bypass grafting (OPCAB) patients. Remote ischemic preconditioning (RIPC) is a noninvasive intervention that may offer multiorgan protection. This study aimed to evaluate the impact of preoperative RIPC on postoperative gastrointestinal function and clinical outcomes in OPCAB patients. This prospective, assessor- and statistician-blinded, sham-controlled, randomized clinical trial included 106 patients scheduled to undergo elective OPCAB. They were randomly assigned to the RIPC (n = 53) or sham-RIPC (n = 53) group. The RIPC group received bilateral upper limb ischemia/reperfusion cycles (200 mmHg, 5-min ischemia/5-min reperfusion, repeated for 5 cycles) twice daily for 3 consecutive preoperative days. The primary outcome was the incidence of postoperative gastrointestinal intolerance (POGI), defined as an I-FEED score of 3-5 within 7 days postoperatively. The secondary outcomes included markers of intestinal injury (intestinal fatty acid-binding protein (I-FABP)), systemic inflammation (interleukin-6 (IL-6), C-reactive protein (CRP)), and S-100 protein beta subunit (S-100β). The exploratory outcomes comprised gut microbiota analysis and other clinical parameters. The incidence of POGI was lower in the RIPC than in the sham-RIPC group (35.4% vs. 56.5%, P = 0.040). The postoperative serum levels of I-FABP, IL-6, CRP, and S-100β were also lower in the RIPC group. Moreover, the relative abundance of Gemella and Dorea decreased in the RIPC group postoperatively. Notably, the abundance of Gemella showed a positive correlation with the postoperative levels of I-FABP and IL-6, whereas that of Dorea exhibited a positive correlation with the postoperative I-FABP levels. The preoperative application of RIPC was associated with a lower risk of POGI, with no observed safety concerns. This effect of RIPC may be related to attenuated intestinal mucosal injury, reduced systemic inflammation, and potential modulation of the gut microbiota. This study was registered on May 30, 2024 (ChiCTR2400085044).
- Open Access
- 6 June 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Plasma albumin and other indicators as risk factors for delayed neurocognitive recovery in elderly patients undergoing orthopedic surgery
The risk factors for neurocognitive impairment outcomes vary among different types of surgeries. The risk factors for delayed neurocognitive recovery (DNR)
- 6 June 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Open AccessPlasma albumin and other indicators as risk factors for delayed neurocognitive recovery in elderly patients undergoing orthopedic surgery
The risk factors for neurocognitive impairment outcomes vary among different types of surgeries. The risk factors for delayed neurocognitive recovery (DNR)
- Open Access
- 18 May 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (5) , e70924
Sugammadex Vs. Neostigmine for Cerebral Perfusion During Emergence From General Anesthesia in Patients Undergoing Carotid Endarterectomy: A Double‐Blind Randomized Controlled Trial
Background: Carotid endarterectomy (CEA) is the standard treatment for carotid stenosis, but has the risk of cerebral hyperperfusion syndrome (CHS). Postoperative residual neuromuscular blockade can trigger cerebral hyperperfusion (CH), and the effects of neostigmine and sugammadex on cerebral perfusion during CEA are unclear. Objective: This study aimed to compare the efficacy of neostigmine combined with atropine and sugammadex in reversing neuromuscular blockade in CEA patients under general anesthesia and evaluate the superiority of sugammadex in maintaining normal cerebral perfusion during anesthesia emergence. Methods: A single‐center, prospective, randomized controlled study was carried out and registered on the Chinese Clinical Trial Registry website (ChiCTR2300078579). Between December 2023 and June 2024, 90 patients were recruited. After exclusions, 82 patients were randomly assigned to the sugammadex group or the neostigmine group at a 1:1 ratio. The primary outcome was the difference in the area under the curve of the percentage of middle cerebral artery velocity relative to baseline (MCAV% S) during emergence. Secondary outcomes included multiple hemodynamic and clinical parameters, as well as pulmonary and CH‐related complications within 48 h post‐operation. Mediation analysis, ROC analysis, and multivariate linear regression analysis were used to illustrate the differences in MCAV%S between the two groups and subsequent analysis. Results: The MCAV% S in the sugammadex group was significantly lower than in the neostigmine group (24,600 [14,940–38,040] vs. 31,575 [24,210–50,040], p = 0.044), and this difference persisted after adjusting for variables (Estimate (95% CI): −10,896 [−21,387 ~ −405]; p = 0.042). The sugammadex group had shorter eye‐opening and extubation times, and a lower incidence of hypoxemia and overall pulmonary complication score. Mediation analysis showed that extubation time mediated part of the effect on MCAV% S, and the ROC analysis indicated good predictive performance of MCAV% S for CH. Conclusion: In CEA patients, sugammadex is more advantageous than neostigmine in reversing neuromuscular blockade during emergence, as it shortens extubation time, reduces excessive cerebral blood flow, and potentially lowers the incidence of postoperative complications.
- 18 May 2026
- Published by Wiley in CNS Neuroscience & Therapeutics
- Vol. 32 (5) , e70924
Open AccessSugammadex Vs. Neostigmine for Cerebral Perfusion During Emergence From General Anesthesia in Patients Undergoing Carotid Endarterectomy: A Double‐Blind Randomized Controlled Trial
Background: Carotid endarterectomy (CEA) is the standard treatment for carotid stenosis, but has the risk of cerebral hyperperfusion syndrome (CHS). Postoperative residual neuromuscular blockade can trigger cerebral hyperperfusion (CH), and the effects of neostigmine and sugammadex on cerebral perfusion during CEA are unclear. Objective: This study aimed to compare the efficacy of neostigmine combined with atropine and sugammadex in reversing neuromuscular blockade in CEA patients under general anesthesia and evaluate the superiority of sugammadex in maintaining normal cerebral perfusion during anesthesia emergence. Methods: A single‐center, prospective, randomized controlled study was carried out and registered on the Chinese Clinical Trial Registry website (ChiCTR2300078579). Between December 2023 and June 2024, 90 patients were recruited. After exclusions, 82 patients were randomly assigned to the sugammadex group or the neostigmine group at a 1:1 ratio. The primary outcome was the difference in the area under the curve of the percentage of middle cerebral artery velocity relative to baseline (MCAV% S) during emergence. Secondary outcomes included multiple hemodynamic and clinical parameters, as well as pulmonary and CH‐related complications within 48 h post‐operation. Mediation analysis, ROC analysis, and multivariate linear regression analysis were used to illustrate the differences in MCAV%S between the two groups and subsequent analysis. Results: The MCAV% S in the sugammadex group was significantly lower than in the neostigmine group (24,600 [14,940–38,040] vs. 31,575 [24,210–50,040], p = 0.044), and this difference persisted after adjusting for variables (Estimate (95% CI): −10,896 [−21,387 ~ −405]; p = 0.042). The sugammadex group had shorter eye‐opening and extubation times, and a lower incidence of hypoxemia and overall pulmonary complication score. Mediation analysis showed that extubation time mediated part of the effect on MCAV% S, and the ROC analysis indicated good predictive performance of MCAV% S for CH. Conclusion: In CEA patients, sugammadex is more advantageous than neostigmine in reversing neuromuscular blockade during emergence, as it shortens extubation time, reduces excessive cerebral blood flow, and potentially lowers the incidence of postoperative complications.
- 15 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 327-330
The carbon footprint of general anaesthesia in adult patients: re-evaluating the environmental sustainability of propofol. Comment on Br J Anaesth 2025; 134: 1620–7
- 15 May 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (1) , 327-330
The carbon footprint of general anaesthesia in adult patients: re-evaluating the environmental sustainability of propofol. Comment on Br J Anaesth 2025; 134: 1620–7
- Open Access
- 27 April 2026
- Published by Science Publishing Group in International Journal of Pain Research
- Vol. 2 (2) , 61-69
New Advances in the Clinical Application of Postoperative Analgesia and Pain Assessment Scales in China
Postoperative pain management is a cornerstone of perioperative medicine, and the accuracy of pain assessment directly determines analgesic efficacy. For decades, Chinese clinical practice has relied heavily on translated versions of foreign pain assessment scales, which often suffer from inadequate cultural adaptation, strong subjectivity, and a unidimensional focus on pain intensity. In 1993, the concept of patient-controlled analgesia (PCA) was introduced in China, followed by widespread clinical adoption by 1998. In 2011, China developed the world's first artificial intelligence PCA (Ai-PCA) pump, with subsequent expert consensus documents published in 2018 and 2024. Leveraging accumulated experience with Ai-PCA, a Chinese research team developed the Smart Patient-Controlled Analgesia Outcome Chinese Pain Assessment Scale (S-CPAS) in 2025. This innovative, intelligent assessment system marks a paradigm shift from subjective, experience-based evaluation to data-driven, multidimensional assessment. The S-CPAS integrates the Pain Comprehensive Index (PCI) – covering pain intensity, functional impacts, adverse reactions, pump operational quality, sedation, and muscle strength – with patient satisfaction scores. It has demonstrated good reliability and validity in multicenter studies. This review systematically examines the past, present, and future of clinical applications of postoperative pain assessment scales in China. We discuss the historical evolution of postoperative analgesia, the limitations of traditional tools, and the core innovations of the S-CPAS in individualization, precision, and intelligence. Future directions include the integration of S-CPAS with the Virtual Pain Unit (VPU) and Acute Pain Service (APS) collaborative management model to enable precision multimodal analgesia (PMA). Other emerging trends are the use of wearable sensors, multimodal physiological monitoring, machine learning-based pain trajectory prediction, and out-of-hospital remote analgesia management. We call for widespread adoption of the S-CPAS-based intelligent assessment platform to promote standardized, high-quality postoperative pain management in China and to contribute to the “Healthy China” strategy.
- 27 April 2026
- Published by Science Publishing Group in International Journal of Pain Research
- Vol. 2 (2) , 61-69
Open AccessNew Advances in the Clinical Application of Postoperative Analgesia and Pain Assessment Scales in China
Postoperative pain management is a cornerstone of perioperative medicine, and the accuracy of pain assessment directly determines analgesic efficacy. For decades, Chinese clinical practice has relied heavily on translated versions of foreign pain assessment scales, which often suffer from inadequate cultural adaptation, strong subjectivity, and a unidimensional focus on pain intensity. In 1993, the concept of patient-controlled analgesia (PCA) was introduced in China, followed by widespread clinical adoption by 1998. In 2011, China developed the world's first artificial intelligence PCA (Ai-PCA) pump, with subsequent expert consensus documents published in 2018 and 2024. Leveraging accumulated experience with Ai-PCA, a Chinese research team developed the Smart Patient-Controlled Analgesia Outcome Chinese Pain Assessment Scale (S-CPAS) in 2025. This innovative, intelligent assessment system marks a paradigm shift from subjective, experience-based evaluation to data-driven, multidimensional assessment. The S-CPAS integrates the Pain Comprehensive Index (PCI) – covering pain intensity, functional impacts, adverse reactions, pump operational quality, sedation, and muscle strength – with patient satisfaction scores. It has demonstrated good reliability and validity in multicenter studies. This review systematically examines the past, present, and future of clinical applications of postoperative pain assessment scales in China. We discuss the historical evolution of postoperative analgesia, the limitations of traditional tools, and the core innovations of the S-CPAS in individualization, precision, and intelligence. Future directions include the integration of S-CPAS with the Virtual Pain Unit (VPU) and Acute Pain Service (APS) collaborative management model to enable precision multimodal analgesia (PMA). Other emerging trends are the use of wearable sensors, multimodal physiological monitoring, machine learning-based pain trajectory prediction, and out-of-hospital remote analgesia management. We call for widespread adoption of the S-CPAS-based intelligent assessment platform to promote standardized, high-quality postoperative pain management in China and to contribute to the “Healthy China” strategy.
- Open Access
- 1 April 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-19
Integrated Bioinformatic Identification and Experimental Validation Reveal That Aging Exacerbates ARDS Through MAPK14/ADM/MAPK8 Axis
To elucidate the molecular mechanisms by which aging exacerbates the severity of the Acute Respiratory Distress Syndrome (ARDS), with a specific focus on identifying and validating a novel signaling axis involving MAPK14, ADM, and MAPK8. We performed an integrated analysis of ARDS gene expression data, focusing on aging and immune-related genes. Our approach included functional enrichment, machine learning, transcription factor prediction, and immune infiltration analysis. Computational drug repositioning identified potential therapeutics. Findings were validated in an LPS-induced murine ARDS model using young and aged mice, with assessments via qRT-PCR, H&E staining, BALF cell counts, and cytokine quantification. Our analysis revealed that MAPK8 was significantly downregulated in ARDS and exhibited a strong negative correlation with IL-10 (r = −0.63). Conversely, MAPK14 and ADM were upregulated and demonstrated a positive association with pro-inflammatory M1 macrophages and γδ T cells. A robust positive correlation was observed between MAPK14 and the transcription factor CEBPA (r = 0.86). Co-enrichment analysis of ADM and MAPK14 at the cisbp__M0666 motif suggested a potential co-regulatory mechanism. Among the candidate therapeutics identified through drug repositioning, fostamatinib emerged as a promising agent to counteract the ARDS-associated expression signature. The in vivo experiments corroborated our computational findings, demonstrating that aging significantly exacerbated ARDS severity. Aged ARDS mice exhibited more severe lung injury, increased neutrophil infiltration, and elevated levels of IL-1β and IL-6. Furthermore, the upregulation of MAPK14 and ADM was more pronounced in aged mice compared to their younger counterparts (P < 0.05), while MAPK8 downregulation was similarly intensified with aging. This integrated study reveals a novel MAPK14/ADM/MAPK8 signaling axis as a key mechanism of age-related inflammatory dysregulation in ARDS. Aging amplifies this pro-inflammatory pathway, worsening tissue damage. Targeting this axis may represent a promising therapeutic strategy for elderly ARDS patients.
- 1 April 2026
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 19, 1-19
Open AccessIntegrated Bioinformatic Identification and Experimental Validation Reveal That Aging Exacerbates ARDS Through MAPK14/ADM/MAPK8 Axis
To elucidate the molecular mechanisms by which aging exacerbates the severity of the Acute Respiratory Distress Syndrome (ARDS), with a specific focus on identifying and validating a novel signaling axis involving MAPK14, ADM, and MAPK8. We performed an integrated analysis of ARDS gene expression data, focusing on aging and immune-related genes. Our approach included functional enrichment, machine learning, transcription factor prediction, and immune infiltration analysis. Computational drug repositioning identified potential therapeutics. Findings were validated in an LPS-induced murine ARDS model using young and aged mice, with assessments via qRT-PCR, H&E staining, BALF cell counts, and cytokine quantification. Our analysis revealed that MAPK8 was significantly downregulated in ARDS and exhibited a strong negative correlation with IL-10 (r = −0.63). Conversely, MAPK14 and ADM were upregulated and demonstrated a positive association with pro-inflammatory M1 macrophages and γδ T cells. A robust positive correlation was observed between MAPK14 and the transcription factor CEBPA (r = 0.86). Co-enrichment analysis of ADM and MAPK14 at the cisbp__M0666 motif suggested a potential co-regulatory mechanism. Among the candidate therapeutics identified through drug repositioning, fostamatinib emerged as a promising agent to counteract the ARDS-associated expression signature. The in vivo experiments corroborated our computational findings, demonstrating that aging significantly exacerbated ARDS severity. Aged ARDS mice exhibited more severe lung injury, increased neutrophil infiltration, and elevated levels of IL-1β and IL-6. Furthermore, the upregulation of MAPK14 and ADM was more pronounced in aged mice compared to their younger counterparts (P < 0.05), while MAPK8 downregulation was similarly intensified with aging. This integrated study reveals a novel MAPK14/ADM/MAPK8 signaling axis as a key mechanism of age-related inflammatory dysregulation in ARDS. Aging amplifies this pro-inflammatory pathway, worsening tissue damage. Targeting this axis may represent a promising therapeutic strategy for elderly ARDS patients.
- Open Access
Association between preoperative COVID-19 and major postoperative pulmonary complications: a multicentre observational cohort study in China
Objective To evaluate the relationship between preoperative COVID-19 infection and major postoperative pulmonary complications (PPC) risk after major elective surgeries during the Omicron wave. Design A multicentre, prospective, observational cohort study. Setting Four tertiary medical centres in Beijing, China. Participants All adult patients who underwent major elective surgeries under general anaesthesia from 30 December 2022 to 18 May 2023 were screened for eligibility. A total of 3211 patients were included. Primary and secondary measures The primary outcome was 30-day major PPC, defined as pneumonia, acute respiratory distress syndrome or unexpected postoperative ventilation. The secondary outcomes included length of hospital stay (LOS), reoperation and mortality. Results Major PPC occurred in 3.5% of patients with preoperative COVID-19 and 3.3% of those without. Inverse probability of treatment weighting-adjusted analysis showed no significant association between preoperative COVID-19 within 12 weeks and PPC risk (adjusted OR, 0.89; 95% CI 0.69 to 1.13). However, multivariable analysis revealed that COVID-19 infection within 3 weeks was independently associated with an increased PPC risk (OR, 3.44; 95% CI 1.37 to 8.68). Cardiothoracic surgery (OR, 12.47; 95% CI 8.11 to 19.17) and longer duration of surgery (OR, 1.24 per hour; 95% CI 1.13 to 1.37) were significant risk factors. In the cardiothoracic subgroup, PPC risk was significantly elevated within 7 weeks of infection. No significant differences were observed in LOS, reoperation rates or mortality between patients with and without preoperative COVID-19 infection. Conclusions Preoperative COVID-19 infection within 12 weeks was not associated with an increased overall risk of major PPC during the Omicron wave. Although very short infection-to-surgery intervals and cardiothoracic surgery showed exploratory signals of higher risk, these findings should be interpreted cautiously and support an individualised approach to perioperative risk assessment. Trial registration number ChiCTR2200067250.
Open AccessAssociation between preoperative COVID-19 and major postoperative pulmonary complications: a multicentre observational cohort study in China
Objective To evaluate the relationship between preoperative COVID-19 infection and major postoperative pulmonary complications (PPC) risk after major elective surgeries during the Omicron wave. Design A multicentre, prospective, observational cohort study. Setting Four tertiary medical centres in Beijing, China. Participants All adult patients who underwent major elective surgeries under general anaesthesia from 30 December 2022 to 18 May 2023 were screened for eligibility. A total of 3211 patients were included. Primary and secondary measures The primary outcome was 30-day major PPC, defined as pneumonia, acute respiratory distress syndrome or unexpected postoperative ventilation. The secondary outcomes included length of hospital stay (LOS), reoperation and mortality. Results Major PPC occurred in 3.5% of patients with preoperative COVID-19 and 3.3% of those without. Inverse probability of treatment weighting-adjusted analysis showed no significant association between preoperative COVID-19 within 12 weeks and PPC risk (adjusted OR, 0.89; 95% CI 0.69 to 1.13). However, multivariable analysis revealed that COVID-19 infection within 3 weeks was independently associated with an increased PPC risk (OR, 3.44; 95% CI 1.37 to 8.68). Cardiothoracic surgery (OR, 12.47; 95% CI 8.11 to 19.17) and longer duration of surgery (OR, 1.24 per hour; 95% CI 1.13 to 1.37) were significant risk factors. In the cardiothoracic subgroup, PPC risk was significantly elevated within 7 weeks of infection. No significant differences were observed in LOS, reoperation rates or mortality between patients with and without preoperative COVID-19 infection. Conclusions Preoperative COVID-19 infection within 12 weeks was not associated with an increased overall risk of major PPC during the Omicron wave. Although very short infection-to-surgery intervals and cardiothoracic surgery showed exploratory signals of higher risk, these findings should be interpreted cautiously and support an individualised approach to perioperative risk assessment. Trial registration number ChiCTR2200067250.
- Open Access
- 9 March 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Effect of intraoperative hypothermia on postoperative pulmonary complications in elderly off-pump coronary artery bypass grafting patients: a retrospective cohort study
Intraoperative hypothermia has significant effects on physiological functions such as anti-infection and coagulation, but its association with specific pos
- 9 March 2026
- Published by Springer Nature in BMC Surgery
- Vol. 26 (1)
Open AccessEffect of intraoperative hypothermia on postoperative pulmonary complications in elderly off-pump coronary artery bypass grafting patients: a retrospective cohort study
Intraoperative hypothermia has significant effects on physiological functions such as anti-infection and coagulation, but its association with specific pos